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Age-related frailty may be due to decreased skeletal
muscle regeneration. The role of TGF-b molecules
myostatin and GDF11 in regeneration is unclear.
Recent studies showed an age-related decrease in
GDF11 and that GDF11 treatment improves muscle
regeneration, which were contrary to prior studies.
We now show that these recent claims are not repro-
ducible and the reagents previously used to detect
GDF11 are not GDF11 specific. We develop a
GDF11-specific immunoassay and show a trend to-
ward increased GDF11 levels in sera of aged rats
and humans. GDF11 mRNA increases in rat muscle
with age. Mechanistically, GDF11 and myostatin
both induce SMAD2/3 phosphorylation, inhibit
myoblast differentiation, and regulate identical
downstream signaling. GDF11 significantly inhibited
muscle regeneration and decreased satellite cell
expansion in mice. Given early data in humans
showing a trend for an age-related increase, GDF11
could be a target for pharmacologic blockade to treat
age-related sarcopenia.
INTRODUCTION
Aging is associated with a decrease in the mass and function of
skeletal muscle, termed ‘‘sarcopenia.’’ Sarcopenia contributes
to the overall frailty that is observed in the elderly. The decrease
in muscle mass and strength observed has been associated with
disability and is unfortunately a reliable predictor of the loss of in-
dependence, and even mortality—independent of other risk fac-
tors (Roubenoff and Hughes, 2000). The molecular mechanisms
that are causal for sarcopenia are thought to be multi-factorial
(Egerman and Glass, 2014). An unbiased profiling study in rats
demonstrated that a decline in mitochondrial pathways and
neuromuscular junction competence were among the primary
perturbations correlated with sarcopenia (Ibebunjo et al., 2013).
Other studies have implicated a role for TGF-b familymembers
in aging and frailty. For example, TGF-b itself has been associ-164 Cell Metabolism 22, 164–174, July 7, 2015 ª2015 Elsevier Inc.ated with the fibrosis seen in older tissue and as an inhibitor of
muscle differentiation (Beggs et al., 2004; Carlson et al., 2009;
Massague´ et al., 1986). Myostatin, also called growth differenti-
ation factor 8 (GDF8), has also been demonstrated to be an
inhibitor of muscle differentiation (McPherron et al., 1997a; Sar-
tori et al., 2009; Trendelenburg et al., 2009). It can also induce
atrophy on post-differentiated myotubes (Sartori et al., 2009;
Trendelenburg et al., 2009). Myostatin null mice (McPherron
et al., 1997a) and cattle demonstrate a doubling in muscle
mass (Kambadur et al., 1997; McPherron and Lee, 1997b).
This increase in muscularity upon the loss of myostatin has
been demonstrated in multiple animals and even in humans
(Lee, 2010). It has also been shown that other TGF-b family mol-
ecules, distinct frommyostatin, play a role in modulating skeletal
muscle size, since myostatin/ mice that are mated with mice
that are transgenic for follistatin (TGfollistatin), which is capable
of inhibiting not only myostatin but also its close relative
GDF11 and other TGF-b molecules, such as the activins (Hill
et al., 2002; Schneyer et al., 2008; McPherron et al., 2009), re-
sulted in an even greater increase in muscle size (Lee et al.,
2010). Myostatin induces cellular signaling by binding either of
the type II activin receptors (IIa or IIb), which then allows for
activation of type I receptors ALK4 or ALK5 (Tsuchida et al.,
2008). The binding of myostatin to these receptor complexes
results in the phosphorylation and activation of the transcription
factors SMAD2 and SMAD3, which translocate to the nucleus
upon phosphorylation (Rebbapragada et al., 2003).
GDF11 is highly related to myostatin, sharing 90% homology
in the mature active regions of both proteins (Nakashima et al.,
1999). As in the case of other TGF-b family members, myostatin
and GDF11 precursor proteins are proteolytically processed to
form biologically active carboxy-terminal dimers. They both
have similar signaling pathways; both bind activin type II recep-
tors and activate the intracellular mediator SMAD 2/3 pathway
(Lee and McPherron, 2001; Oh et al., 2002; Sartori et al., 2009;
Trendelenburg et al., 2009; Tsuchida et al., 2008). While myosta-
tin is predominantly expressed in developing and adult skeletal
muscle (Bass et al., 1999; Gonzalez-Cadavid et al., 1998; Ji
et al., 1998; Kambadur et al., 1997), GDF11 expression is quite
different (Nakashima et al., 1999). GDF11/mice display home-
otic transformations of the axial skeleton, without an obvious
effect on skeletal muscle (McPherron et al., 1999), although it
is a negative regulator of myogenesis and chondrogenesis in
the developing chick (Gamer et al., 2001). While the phenotypes
caused by myostatin versus GDF11 deletion appear to be
nonoverlapping, the high sequence identity and similarity in
signaling mechanisms suggest the two molecules may be func-
tionally redundant and that the different phenotypes are due to
differences in sites of expression.
A couple of recent manuscripts reported that GDF11 has
distinct effects in comparison to myostatin. In one case, it
was reported that GDF11 decreased cardiac-related muscle
hypertrophy (Loffredo et al., 2013); in this study it was also
shown that GDF11 levels decreased as a function of age in
mice, and therefore it was suggested that replenishment of
GDF11 would help block cardiac muscle hypertrophy. Later,
in a distinct study, another group showed that GDF11 had pos-
itive effects on aged satellite cells (SCs) and an improvement in
skeletal muscle regeneration when GDF11 was administered to
older mice (Sinha et al., 2014). These more recent findings
seemed surprising given that the very closely related myostatin
is a direct inhibitor of muscle differentiation (Rı´os et al., 2002;
Trendelenburg et al., 2009; Sartori et al., 2009). Therefore,
given the claimed dramatically positive effects of GDF11 on
skeletal muscle, in contrast to the demonstrated negative ef-
fects induced by myostatin, it seemed important to study the
role of GDF11 in particular on skeletal muscle both in vitro
and in vivo.
RESULTS
Prior Reagents Used to Detect GDF11 Are Not GDF11
Specific
Previous reports had identified GDF11, through both proteomic
and western blot analyses, as a circulating factor in mice whose
serum levels decrease with age (Loffredo et al., 2013; Sinha
et al., 2014). In the Loffredo study, the SOMAmer technology
was used to make an assessment of GDF11 levels. We first
sought to test the specificity of the GDF11 SOMAmer used in
the prior study by determining whether it might cross-react
with myostatin. This seemed possible given the 90% sequence
identity between the two proteins in their mature active form.
In a direct binding test of GDF11 and myostatin, we observed
that the GDF11 SOMAmer does indeed bind both proteins
(Figure 1A, apparent KD for GDF11: 6.6 ± 1.1 nM; for myostatin:
11.8 ± 1.1 nM), while a chemically related control SOMAmer
binds neither protein (data not shown). Since the SOMAmer
that was previously used to demonstrate a decrease of GDF11
levels in age actually could not distinguish between myostatin
and GDF11, we next tried the antibody that was used to demon-
strate that GDF11 declines with age (Loffredo et al., 2013; Sinha
et al., 2014). This antibody was also first tested for its specificity.
By western blot analysis, the antibody was found to recognize
both recombinant myostatin and GDF11 to a similar degree,
indicating cross-reactivity and a lack of preferential binding to
GDF11 (Figure 1B). Importantly, under the reducing conditions
used in this study, both the mature dimer (25 kDa) and reduced
monomer (12.5 kDa) of recombinant myostatin and GDF11
were observed. In addition, some higher molecular weight
material was observed, consistent with aggregated GDF11 or
myostatin, since the molecular weight of the higher bands are
multiples of the monomer.The Combination of Myostatin and GDF11 Increases in
Mouse Sera
Nevertheless, reasoning that we could at least confirm whether
the combination of myostatin and GDF11 declined with age, as
had been previously reported by detection with this antibody,
serum samples from young and old mice were analyzed by
western blot to determine the relative abundance of myosta-
tin/GDF11 in mouse blood. Although the level of monomer
decreased with age, as had been previously reported, the active
dimer was also observed, and its level actually significantly
increased (Figure 1C and Figure S1A). Both the monomer band
and the dimer band co-migrated with recombinant GDF11 (Fig-
ure 1C and Figure S1A). We were assured that we were able to
detect actual GDF11 in the serum by injecting young mice with
recombinant GDF11; with the antibody, we could then observe
an increase in the dimer band, corresponding to an overall
increase in serum GDF11 levels (Figure S1B). A Coomassie
stained gel is also provided to demonstrate equivalent protein
loading (75 mg total protein/lane) (Figure 1C) and a Ponceau stain
is provided in a second experiment, repeating these results (Fig-
ure S1A). Overall, it appears that the total levels of myostatin/
GDF11 actually increase with age, contradicting the prior reports
(Loffredo et al., 2013; Sinha et al., 2014).
A GDF11-Specific Method Demonstrates a Trend of
GDF11 Increasing with Age in Rat and Human Sera
In order to specifically detect the levels of GDF11 in serum sam-
ples, an immunoassay was established that was validated to be
specific for GDF11 (Figures S2A and S2B). This immunoassay
did not detect myostatin (Figures S2A and S2B). The validation
work further established that the immunoassay could detect
endogenous GDF11 in human sera (Figure S2C, bar graph on
left, blue bars) and that it was actually measuring GDF11,
since recombinant GDF11 when spiked into human sera was
detected (Figure S2C, bar graph on left, red bars). Furthermore,
when sera were diluted, GDF11 was recovered in proportion to
that dilution, demonstrating that the assay can quantitatively
measure GDF11 within a range, even when it is diluted (Fig-
ure S2C, graph on right). With this assay, we could not detect
endogenous GDF11 in either young or old mice (data not
shown), since the levels were below the sensitivity of detection
for this immunoassay. We next tried to detect GDF11 in sera
from other species. We measured the blood serum concentra-
tion of GDF11 in both young and old rats (6 months versus
24 months) and humans (20–30 years versus 60+ years). We
found that there was a nearly significant increase of GDF11
(1.4 fold increase, p = 0.0534) in serum from older rats
compared to the younger rats (Figure 1E). A similar trend toward
an increase in median levels was observed comparing serum
from humans over the age of 60 in comparison to sera from
humans between 20 and 30 years old (Figure 1F).
GDF11 Expression Increases with Age in Rat Skeletal
Muscle
To use a distinct method to detect GDF11 specifically, we
performed RNA-seq on skeletal muscle from the rats, using
6-, 12-, 18-, 21-, and 24-month-old animals (Ibebunjo et al.,
2013), spanning the lifespan of the animal. This study demon-
strated that GDF11 expression increased dramatically as aCell Metabolism 22, 164–174, July 7, 2015 ª2015 Elsevier Inc. 165
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Figure 1. Prior Reagents Used to Measure
GDF11 Are Not Specific, but Show that the
Combination of GDF11 and Myostatin In-
creases with Age; Specific Methods show
GDF11 Levels Increase with Age
(A) Affinity of GDF11 SOMAmer for recombinant
GDF11 and myostatin. Binding of the GDF11
SOMAmer to GDF11 (shown in blue) andmyostatin
(shown in red) proteins as measured by dissocia-
tion-enhanced lanthanide fluorescent immuno-
assay (DELFIA). Data represent means ± SD from
three technical replicates.
(B) Western blot analysis to determine specificity
of Abcam antibody to GDF11 versus myostatin
(GDF8). An anti-GDF11 antibody from Abcam was
tested for specificity using a concentration
gradient of recombinant GDF11 and myostatin,
ranging from 6.25 ng to 100 ng, and was found to
cross-react with myostatin. Even though this is a
denaturing gel, bands consistent with dimer and
even high molecular forms consistent with aggre-
gates of the recombinant material are evident.
(C) Western analysis on sera from young and old
mice. Sera samples from four different young ani-
mals (4 months old; 1, 2, 3, 4) and four different old
animals (23 months old; 5, 6, 7, 8) were tested by
western analysis for myostatin/GDF11 levels (top).
Coomasie staining (bottom) demonstrates equiv-
alent loading of each lane. Lane with ladder is
indicated. The dimer band was not fully denatured
to monomer. There was an increase in GDF11/
myostatin dimer levels in the sera from older
animals in comparison to young animals. Densi-
tometry of monomer + dimer is provided on the
right, indicating an overall increase in myostatin/
GDF11 levels in the mouse sera (*p < 0.05).
(D) GDF11 and myostatin mRNA content in in
skeletal muscles of Sprague-Dawley male rats
aged 6, 12, 18, 21, and 24 months (data derived
from the RNA-seq analyses). RNA-seq analysis
demonstrates that GDF11 expression increases as
a function of age (comparing mRNA obtained from
muscles from 6-, 12-, 18-, 21-, and 24-month-old
rats). In contrast, myostatin (MSTN) expression
decreases with age in rats. The y axis is the stan-
dardized expression level, with mean of 0 and
standard deviation of 1. GOF, goodness of fit to a
sigmoidal curve; FC, fold change between 24 m
and 6 m.
(E) GDF11 protein levels in sera from young and old rats determined by immunoassay. GDF11 protein content in serum from young (6 months) or old (24 months)
rats was measured by immunoassay. Old rats had higher levels of GDF11 compared with young. Data are mean ± SEM (p = 0.0534, Student’s t test).
(F) GDF11 protein levels in sera from young and older humans determined by immunoassay. GDF11 protein content was measured in serum samples from nine
older (aged >60 years, males, shown in red) or ten young (aged 20-30 years, males, shown in blue). The median GDF11 concentration in serum of older humans
was higher than in younger humans, but this did not reach statistical significance. Serum samples from three young and one old subject had GDF11 below a
detection limit (less than 0.274 ng/ml), shown with a dotted horizontal line.function of age, while surprisingly, myostatin expression was
shown to decrease with age (Figure 1D). These findings were
confirmed by qPCR in a distinct cohort (Figure S1C).
GDF11 and Myostatin Similarly Induce SMAD, p38, and
ERK Phosphorylation
To rationalize whether GDF11 could have distinct effects in
comparison to myostatin, we decided to compare the two mol-
ecules for their ability to induce signaling and cellular effects
in vitro. Human skeletal muscle-derived cells (hSkMDCs) were166 Cell Metabolism 22, 164–174, July 7, 2015 ª2015 Elsevier Inc.used, since human cells were shown to respond to TGF-b fam-
ily members at physiological concentrations in a prior study
(Trendelenburg et al., 2009). Differentiated hSkMDC myotubes
were serum-starved and then treated with multiple doses of
either recombinant protein. Myostatin and GDF11 treatment
both resulted in increases in SMAD2 and SMAD3 phosphor-
ylation, and these increases occurred in a concentration-
dependent manner (Figure 2A). Myostatin and GDF11 activated
SMAD2/3 transcription factor function, as indicated by dose-
dependent increases on CAGA-luc SMAD reporter activity
(Figure 2B). These data demonstrate that myostatin and GDF11
can signal through SMAD2/3 activation in skeletal muscle
and other cells. Since myostatin is also able to signal via the
mitogen-activated protein kinase (MAPK) pathways (ERK1/2,
JNK, p38) (Philip et al., 2005; Yang et al., 2006), GDF11 and
myostatin were compared for their ability to activate p38 and
ERK. Indeed, treatment with myostatin and GDF11 also in-
creased phosphorylation of p38 and ERK in C2C12 cells, indi-
cating that both GDF11 and myostatin induce signaling via
these pathways to a similar degree (Figure S3).
GDF11 and Myostatin Both Inhibit Myoblast
Differentiation
We next sought to compare the phenotypic effects of myostatin
and GDF11 in hSkMDCs, in a muscle cell culture system from
human adult donor cells, to see if they might have divergent
effects on differentiation. This seemed to be relevant since
it was claimed that GDF11 improved regeneration in older
mice—therefore, one might expect to see an improvement in
myoblast differentiation brought on by GDF11 treatment. This
was especially of interest since it was previously reported that
in fetal donor cells the TGF-b family actually blocks skeletal mus-
cle differentiation—specifically, myostatin, GDF11, TGF-b1, and
activin A have all been shown to block myogenic differentiation
with varying degrees of potency (Gamer et al., 2001; Rı´os
et al., 2002; Trendelenburg et al., 2009). Therefore, human
primary myoblasts were differentiated for 3 days in either the
presence or absence of recombinant myostatin or GDF11
(10 ng/ml or 300 ng/ml). Cell cultures were fixed and immuno-
stained with antibodies against myosin heavy chain (MyHC)
(and DAPI to visualize nuclei) to assess myotube formation
(Figure 2C). Treatment with either recombinant myostatin or
GDF11 led to a decrease in the number of myotubes (Figure 2C).
Inhibition of differentiation was observed at both doses for
GDF11, while only a high dose of myostatin resulted in a similar
effect. The decrease was quantified by determining the percent-
age of nuclei that were positive for MyHC. Both myostatin and
GDF11 significantly decreased the percentage ofMyHC-positive
fibers (Figure 2C). Therefore GDF11, like myostatin, is a direct
inhibitor of skeletal muscle differentiation.
GDF11 and Myostatin Induce Almost Identical Gene
Changes
Even though we demonstrated similar direct signaling of GDF11
and myostatin and that this correlated to inhibitory effects
by both molecules on the differentiation of human skeletal
myoblasts, it was still formally possible that GDF11 might have
some unique activity on muscle, distinct from its activation of
ActRII/ALK/SMAD signaling. We thought the most unbiased
way to approach this possibility was to perform a microarray
study on myotubes with and without stimulation with myostatin
and GDF11 and to then ask if there were any differences in
gene activation. Any unique effect of GDF11 in comparison to
myostatin should be captured by seeing a differential down-
stream modulation of gene expression. Human primary muscle
cells were stimulated for 24 hr with 300 ng/ml of myostatin, or
GDF11, or buffer alone (as a negative control), and the log fold
change in gene expression was examined. The effect on gene
expression induced by GDF11 in comparison to myostatin wasessentially identical (Figures 3A and 3B). Therefore, we could
not detect any unique effect of GDF11 on skeletal muscle cells
in comparison to myostatin; both seem to behave identically—
and their effects are inhibitory.
GDF11 Inhibits Muscle Regeneration
We next sought to corroborate claims that GDF11 administration
improved regenerative capacity of skeletal muscle in aged mice
(Sinha et al., 2014). Therefore, 23-month-old C57BL/6 mice were
treated with GDF11 (0.1 mg/kg) or Vehicle for 28 days to attempt
to ‘‘rejuvenate the stem cell pool’’ prior to receiving a cardiotoxin
(CTX) injection into the tibialis anterior muscle. Treatments were
continued for an additional 7 days after CTX was administered,
and then animals were necropsied. In this initial experiment,
the animals were sacrificed at 7 days post-CTX treatment
because in the prior study reporting positive effects on regener-
ation, this 7-day time point was used (Sinha et al., 2014). In our
study, no differences were observed in regenerative capacity
of skeletal muscle of aged mice treated with GDF11 or Vehicle
at the 7-day time point (Figure S4). In addition, the number of
Pax7+ cells between control and GDF11-treated aged mice
was not different (Figures S5A and S5B). This argues against
the ‘‘rejuvenating’’ potential of GDF11 on the aged muscle
stem cell pool in vivo.
Next we wanted to determine whether higher systemic levels
of GDF11 could positively impact muscle regeneration in set-
tings where GDF11 was lower, which in our study was in younger
mice. Therefore, we administered a 3-fold-higher dose of GDF11
(0.3 mg/kg) than what was used in the prior experiment. Sixteen-
week-old C57BL/6mice were administered GDF11 or Vehicle for
3 days prior to receiving a CTX injection into the tibialis anterior
muscle, and GDF11 was administered daily throughout the
study. Mice were necropsied 14 days following CTX injections.
Classically, in this sort of approach, injured fibers are scored
by looking for central nuclei, which is a marker of regeneration.
When muscle is first formed, the nuclei are in the center of the
fiber, and then over the next 50 days (in mice), they migrate to
the periphery; therefore, if one observes a nucleus in the center
of the fiber, it is a sign that the muscle fiber has recently formed
and is actively regenerating. However, in this study, we noticed
that in the GDF11-treated muscle, there were fibers that were
so small that one could not even appreciate the location of the
nuclei—this is a sign of absolutely nascent myofibers. Therefore,
we decided to present the fiber distributions both by the usual
way, where central nuclei could be definitively determined, and
by simply presenting all of the fibers within the area of injury. In
regenerating muscle, GDF11 treatment was associated with a
greater frequency of small fibers with centralized nuclei (CN),
as indicated by a moderate leftward shift in frequency distribu-
tion (Figure 4A). This, however, did not result in a significant
change in total mean fiber cross-sectional area (Figure 4B).
When we narrowed our focus to the smaller fibers with clear
central nuclei (%600 mm2), to see if there was a shift in this pop-
ulation, we observed a statistically significant reduction in the
mean area with GDF11 treatment (p = 0.0045; Figure 4C).
Next, we expanded our analysis to include all fibers within the
area of injury (i.e., fibers that were both positive for CN and those
wherewe could not determine nuclear localization). Interestingly,
we observed a striking leftward shift in the GDF11-treatedCell Metabolism 22, 164–174, July 7, 2015 ª2015 Elsevier Inc. 167
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Figure 2. GDF11 and Myostatin Signal through Identical Pathways in Skeletal Muscle
(A) Western blot analysis to determine myostatin versus GDF11 activation of downstream signaling. Human myotubes were stimulated with vehicle (UNT), as a
negative control, or with increasing doses of myostatin or GDF11 (10, 30, 100, 300 ng/ml). Both proteins stimulated SMAD2 and SMAD3 phosphorylation
(pSMAD2 and pSMAD3) in a dose-dependent manner.
(legend continued on next page)
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animals (Figure 4D), consistent with the idea that regeneration
had been delayed, since there were so many more tiny myofib-
ers. Consequently, mean area was significantly reduced in total
fibers (p = 0.028; Figure 4E) and in fibers% 600 mm2 (p = 0.014;
Figure 4F) with GDF11 treatment. Histological analysis of tissue
sections stained with anti-laminin antibodies and Hoechst
showed that muscles from GDF11-treated mice contained
numerous pockets of small densely packed fibers that were
positive or undetectable for CN (yellow dashed box; Figure 4G),
suggesting delayed regeneration. These pockets with small
fibers were also evident on H&E-stained muscle sections (Fig-
ure 4H). Therefore, in contrast to what had been shown in the
previous study (Sinha et al., 2014), higher systemic levels of
GDF11 are associated with impaired regeneration, as indicated
by a greater number of very small myofibers in the GDF11-
treated muscles.
GDF11 Decreased the Growth of Adult and Aged SCs
Finally, we sought to examine the impact of GDF11 on growth
and lineage progression of SCs from adult and aged muscle,
since an improvement in regenerative capacity could be due to
a positive effect on SCs. SCs (Lin, Inta7+, VCAM+, and PI) iso-
lated by flow cytometry were cultured in high-serum conditions
(20% FBS) in 96-well plates (200 cells per well) in GDF11 or
vehicle for 3 days. SC cultures were stained for Pax7, MyoD,
and Myogenin (Myog), which are markers of muscle differentia-
tion, and counted using automated software analysis (Figures
5A–5C). Quantification of cell number based on DAPI shows
that treatment with GDF11 decreased the growth of adult and
aged SC cultures in a dose-dependent manner (Figures 5B
and 5C). Analysis of myogenic fate markers did not reveal any
significant changes in their expression, suggesting that GDF11
does not impact cell fate of SCs (Figures S5C and S5D). There-
fore, GDF11 limits the expansion of adult and aged SCs and their
progeny.
To analyze the growth of SCs in their niche, single muscle fi-
bers were isolated from adult mice and cultured for 3 days in
the absence or presence of GDF11 (Figure 5D). Quantification
based on Pax7 and Myog immunohistochemistry reveals a
significant decline in myogenic cell numbers in GDF11-treated
compared to vehicle-treated fibers (Figure 5E). In contrast,
lineage commitment was not impacted (Figure 5F). Therefore,
GDF11 limits the expansion of adult SCs resident in their niche.
This result is inconsistent with a restorative role of GDF11.
Rather, treatment with exogenous GDF11 promotes an age-
related SC phenotype.
DISCUSSION
Aging is often associated with the onset of frailty, caused by the
associated loss of skeletal muscle known as sarcopenia, and a(B) SMAD2/3 reporter assay. A CAGA-luc reporter gene assay treated with either
Data are expressed as chemiluminescence units, relative to untreated, and show
(C)Humanmyoblast differentiationassay.Myoblastsweredifferentiated intomyotu
control, and two concentrations of myostatin (GDF8) (10 ng/ml and 300 ng/ml) a
treatment,withmyotubes identifiedusinganti-MyHCantibodystaining.Bothmyost
in the bar graph by evaluating the percentage of nuclei within myotubes that wer
groups were analyzed using one-way ANOVA (compared to UNT group). Data aredecrease in the ability of SCs to respond to injury by helping
regenerate the muscle. One way to approach treating aging-
related conditions might be to search for secreted molecules
that are regulated with age and then ask whether returning
them to levels more commonly seen in younger animals might
be beneficial.
That is why it seemed to make sense that in prior studies just
such an approach was taken (Loffredo et al., 2013; Sinha et al.,
2014). The combination of these two reports demonstrated
that the myostatin-related factor GDF11 decreased with age
and that treating older micewith GDF11 improvedmuscle regen-
eration (Sinha et al., 2014), a process that is impaired in elderly
animals, including humans. However, the beneficial finding of
GDF11 treatment on skeletal muscle was quite surprising, since
GDF11 is closely related structurally to myostatin and myostatin
has been well published for its ability to inhibit muscle differenti-
ation and to induce muscle atrophy.
The present study contradicts every aspect of the prior studies
as they relate to skeletal muscle. We demonstrate first that
GDF11 cannot be shown to decrease in mouse sera; we found
that the reagents used in the prior studies are not GDF11 spe-
cific, since they pick upmyostatin aswell, but use of the antibody
shows an increase rather than a decrease in GDF11/myostatin
levels if you include both GDF11/myostatin bands that the anti-
body identifies, which includes the active dimer. The upper
band was not presented in the prior studies (Loffredo et al.,
2013).
Fortunately, we were able to develop a new immunoassay
method to specifically measure GDF11 in blood; the validation
work for this immunoassay is presented in this study, in the
Supplemental Information, where we show that GDF11 and not
myostatin can be detected in a quantitative manner, including
in serum. Using this immunoassay, we show that GDF11 can
be specifically measured in the sera of rats and humans. There
is a strong trend for GDF11 increasing in the blood serum of
rats, and there is a dramatic increase in GDF11mRNA in rat skel-
etal muscle, which undergoes sarcopenia when they age (Ibe-
bunjo et al., 2013). In humans, we found just a trend toward an
increase in blood serum, which at the very least shows that
GDF11 does not seem to decline in humans as a function of age.
Consistent with the demonstration in the present study that
GDF11 increases with age, in a prior study we demonstrated
that the downstreammyostatin/GDF11 signaling pathway, char-
acterized by SMAD3 phosphorylation, is also elevated in the
aged rat (Trendelenburg et al., 2012). Given the combination of
these findings, the implication would be that it would be delete-
rious to add even more GDF11 to an aged animal, as one would
do by giving GDF11 as a treatment, since this pathway is inhib-
itory to muscle regeneration. Our current study validates this
concern, since supplementation of GDF11 was found to dramat-
ically inhibit muscle regeneration.myostatin (GDF8) or GDF11 was used to assess recombinant protein activity.
n as means ± SEM. Both myostatin and GDF11 were shown to be active.
beswithoutany treatment () asanegativecontrol, TNF-a (30ng/ml) asapositive
nd GDF11 (10 ng/ml and 300 ng/ml). Biological triplicates are shown for each
atinandGDF11canblockmyoblast differentiation.Differentiationwasquantified
e positively identified using anti-MyHC antibody staining. Differences between
means ± SEM. Values were considered statistically significant at p < 0.05 (*).
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Figure 3. Microarray Analysis of hSkMDCs Treated
with GDF11 or Myostatin Demonstrate that GDF11
and Myostatin Induce Almost Identical Expression
Changes
(A) The log fold-change (FC) versus control samples for
samples (n = 4 biological replicates per group) stimulated for
24 hr with 300 ng/ml myostatin or GDF11 (x and y axes,
respectively). Data points are colored by absolute FC dif-
ference, with darker points representing larger differences.
Reference lines are included for log FC differences of 1/1
(dashed) and 0 (solid).
(B) Gene expression was generated for hSkMDCs treated
with GDF11 or myostatin. There were 243 genes (356 probe
sets) regulated by either GDF11 or MSTN. Intensities are
shown for vehicle and the two treatments (GDF11 and
myostatin; 24 hr at 300 ng/ml). Blue, low expression; red,
high expression; gray, median expression. Genes are
regulated similarly by GDF11 and MSTN.
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Figure 4. GDF11 Delays Regeneration of Tibialis Anterior Muscle following Cardiotoxin Injury
(A–D) In regenerating fibers positive for centralized nuclei, GDF11 treatment induced (A) a leftward shift in fiber cross-sectional area frequency distribution, but no
change in (B) total mean fiber area; however, (C) mean fiber area of fibers with cross-sectional areas% 600 mm2 was significantly reduced with GDF11 treatment
(p = 0.0045). In GDF11-treated mice, regenerating muscles had (D) a greater frequency of smaller-size fibers (positive and undetectable for centralized nuclei).
(E and F) Total mean fiber area (E) and mean area of fibers % 600 mm2 (F) was significantly decreased with GDF11 treatment (p = 0.028 and p = 0.014,
respectively).
(G) Representative images of regenerating tibialis anterior muscles stained with an anti-laminin antibody (green) and Hoechst (blue) show regions of much smaller
fibers that are indicative of delayed regeneration (yellow dashed box) with GDF11 compared to Vehicle treatment.
(H) Representative images of H&E-stained tissues showing region of delayed regeneration with GDF11 treatment. *p < 0.05, **p < 0.01. CN, centralized nuclei.
Scale bar, 100 mm.Since there is a trend of GDF11 increasing in sera from humans
as a function of age, that finding introduces the question as
to whether GDF11 blockade might be helpful to treat age-asso-
ciated human muscle pathology. What was striking was
that there were a couple of aged individuals with especially
high levels of GDF11. So perhaps a detection assay would beappropriate in humans, and if they were found to have very
high levels of GDF11, and this was coincident with muscle pa-
thology, then those individuals might be candidates for either
GDF11-specific blockade or for a more general blockade of
the GDF11, myostatin, and activin receptor, ActRII (Lach-Trifilieff
et al., 2014).Cell Metabolism 22, 164–174, July 7, 2015 ª2015 Elsevier Inc. 171
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Figure 5. GDF11 Limits Satellite Cell Expansion in Adult and Aged Mice
(A) Representative Pax7 (magenta) and MyoD (green) immunostaining of adult SCs after 3 days in culture treated with GDF11 (50 ng/ml) or vehicle control. DAPI
marks myonuclei (white).
(B and C) Histograms show the total number of (B) adult and (C) aged myogenic cells per well after 3 days of GDF11 (15 ng/ml, low or 50 ng/ml, high) or vehicle
control treatment in culture (n = 1,645–2,185 cells, performed in triplicate).
(D) Single muscle fibers from control (top) and GDF11-treated (bottom) 3-day cultures show Pax7+ (red) and myogenin (Myog)+ (green) cells. DAPI highlights
myonuclei (blue). Arrowheads show representative cells.
(E and F) Data are represented as mean ± SD. Cell growth assays were statistically analyzed by Kruskal-Wallis nonparametric test with Dunn’s post hoc test
(*p < 0.05). Student’s t test was performed on single-fiber data followed by a Mann-Whitney U post hoc test (**p < 0.01).EXPERIMENTAL PROCEDURES
DELFIA Immunoassay for SOMAmer Binding
SOMAmers against GDF11 and NR3C1 (negative control) were made synthet-
ically (Integrated DNA Technologies) with a photocleavable biotin moiety at the
50 end and benzyl-modified dUTP nucleotides as previously described (Gold
et al., 2010). GDF11 and myostatin (R&D Systems, #1958-GD and #788-G8,
respectively) were coated onto DELFIA (dissociation-enhanced lanthanide
fluorescent immunoassay) microtitration plates (Perkin Elmer, #1244-550) at
2 mg/ml in 100 mM carbonate buffer (pH 9.6) overnight and washed thoroughly
with PBS containing 0.05% Tween 20. SOMAmers were diluted to 10 mM in
5 mM HEPES (pH 7.5), heated to 85C for 5 min and cooled to room temper-
ature for 15 min, then further diluted in assay buffer (40 mM HEPES, 100 mM
NaCl, 5 mM KCl, 5 mM MgCl2, 1 mM EDTA, 0.05% Tween 20, 0.5 mM dextran
sulfate, 1% BSA) and added to the protein-coated plates for 30 min. Plates
were then washed and incubated with Eu-labeled streptavidin (Perkin Elmer,
#1244-360) for 45 min, followed by DELFIA enhancement solution (Perkin
Elmer, #1244-105) for 15 min, and read on an EnVision 2103 multilabel reader
according to manufacturer recommendations. Data were fit using a three-
parameter nonlinear regression curve fit with a fixed Hill slope in GraphPad
Prism v. 6.04.
Cell Culture and Protein Treatment
hSkMDCs (adult donor; Cook Myosite) were cultured in growth medium con-
sisting of MyoTonic basal medium (Cook Myosite) supplemented with 20%
FBS (Hyclone) and MyoTonic serum-free growth supplement (Cook Myosite).
Differentiation was initiated 24 hr after seeding (day 0) by changing to serum-
free differentiation medium consisting of MyoTonic differentiation medium
(Cook Myosite) containing 2% horse serum (Hyclone) and 1% FBS and172 Cell Metabolism 22, 164–174, July 7, 2015 ª2015 Elsevier Inc.altering the atmospheric conditions from 5% to 7.5% CO2. Cells were
switched back to growth medium on day 4 for 48–72 hr before returning to
differentiation medium prior to treatments of myotubes. To assess effects
on hSkMDC differentiation, compounds were added at day 0 at the onset
of differentiation, and cells were differentiated into myotubes for 72 hr. To
assess effects on mature hSkMDC myotubes, compounds were added either
on day 6 for an additional 24 hr or on day 7. For signaling experiments,
hSkMDC myotubes were serum starved for 3–4 hr and treated for 30 min
prior to harvesting. HEK293T cells stably transfected with pGL3-CAGA12-
luc were grown in culture medium containing 10% FBS at 5% CO2 and sub-
sequently seeded in serum-reduced, phenol red-free assay medium (2%
FBS) for 24 hr at 7.5% CO2. Cells were stimulated with compounds for
another 24 hr prior to analysis. Murine C2C12 myoblasts (American Type
Culture Collection [ATCC]) were maintained in defined media. Myoblasts
were fused into myotubes at confluence by shifting from growth medium
(DMEM/10% fetal bovine serum) to differentiation medium (DMEM/2% horse
serum) and altering the atmospheric conditions from 5% to 7.5% CO2. Cells
were differentiated into myotubes for 96 hr prior to treatment on day 4 myo-
tubes. C2C12 myotubes were serum starved for 4 hr and treated for 30 min
for signaling experiments.
Biochemicals and Antibodies
Myostatin (or GDF8), GDF11, and TNF-a were from R&D Systems. Stock
solutions were prepared as per the manufacturer’s instructions, either in
PBS with 0.1% BSA (TNF-a) or in 4 mM HCl supplemented with 0.1% bovine
serum albumin (BSA; supplemented only for in vitro experiments) (myostatin
and GDF11). For immunostaining, primary antibody against MyHC (clone
A4.1025) was from Upstate (#05-716); secondary antibody (Alexa Fluor
488 F [AB]) was from Invitrogen (#A11017). For western blot analysis, antibody
against GDF11 was from Abcam (#ab124721); antibody against phospho-
Smad2 (Ser465/467) (pSmad2) was from Thermo Scientific (#MA5-15122l);
antibodies against phospho-Smad3 (Ser423/425) and Smad2/3 were from
Cell Signaling (#9520S and #3102, respectively); antibodies against phos-
pho-p38 and p38 were from Cell Signaling (#9211S and 9212S, respectively);
antibodies against phospho-Erk1/2 and Erk1/2 were from Cell Signaling
(#9101L and 9102L, respectively); antibody against GAPDHwas fromGenetex
(#GTX627408). As secondary antibodies, the following were used: goat anti-
rabbit IgG horseradish peroxidase (HRP) and goat anti-mouse IgG HRP from
Cell Signaling (#7074S and #7076S, respectively). For the GDF11 immuno-
assay, standard 96-well MULTI-ARRAY plates and 4X MSD (Meso Scale
Discovery) Read Buffer with Surfactant were acquired from MSD. Phos-
phate-buffered saline (PBS; pH 7.0), PBS with 0.05% v/v Tween 20 (PBST),
PBSwith 3%BSA, and PBSwith 1%BSAwere prepared in-house. Themouse
anti-human GDF11 (clone 743833) was purchased from R&D Systems. Ruthe-
nium-labeled mouse anti-human GDF11 (clone 743833) was prepared in-
house per the manufacturer’s recommendations.
Western Blot Analysis
HSkMDCs and C2C12 cells were homogenized in RIPA lysis buffer (Boston
BioProducts) supplemented with protease and phosphatase inhibitors
(Roche). Homogenates were centrifuged for 15 min at 4C (13,000 rpm) and
supernatants were collected. Protein quantification was performed using bi-
cinchoninic acid (BCA) kit (Pierce). Samples were diluted in SDS-PAGE sample
buffer (63 reducing buffer, Boston BioProducts) and denatured for 5 min at
95C. Equal or equivalent amounts of protein (75 mg for all serum samples;
4 ml of plasma from single mouse per time point, Figure S1B) were loaded
per lane of 4%–12% Bis-Tris NuPAGE gels, electrophoresed, and then trans-
ferred onto PVDF membranes using a wet transfer technique. Ponceau S stain
was applied to PVDF membranes to ensure even transfer, or a second gel
was run in parallel for Coomassie staining. Membranes were blocked in Tris-
buffered saline (TBS) with 0.05% Tween 20 (TBST) with 5% (wt/vol) nonfat
milk powder for 1 hr. Primary antibodies were incubated overnight in TBST
with 5% BSA, and secondary antibodies were incubated in TBST with 5%
nonfat milk. Immunoreactivity was detected by Amersham ECL western
blotting detection reagents (GE Healthcare), Peirce ECL Plus western blotting
substrate, or SuperSignal West Femto Maximum Sensitivity Substrate and
exposed to film.
GDF11-Specific Assay
High Bind 96-well MULTI-ARRAY plates were coated with 50 ml/well of
2 mg/ml mouse anti-human GDF11 (clone 743833) in PBS overnight at 4C.
After washing with PBST, 300 ml of PBS with 3% BSA was added to each
well and incubated with shaking at room temperature for 1–2 hr, followed
by washing with PBST. An eight-point calibration curve was prepared using
3-fold dilutions, starting with a prepared sample of 100 ng/ml recombinant
human GDF11 in PBS with 1% BSA. PBS with 1% BSA was used as a blank.
Samples were diluted 1:2 in PBS with 1% BSA. Fifty microliters of the calibra-
tion curve dilutions or samples was added to duplicate wells and incubated
with shaking for 3 hr at room temperature. Following a PBST wash, 50 ml
of ruthenium-labeled mouse anti-human GDF11 (clone 743833) diluted to
4 mg/ml in PBS with 1% BSA was added to each well and allowed to incubate
in the dark with shaking for 2 hr at room temperature. After another PBST
wash step and addition of 150 ml/well 2X MSD Read Buffer with Surfactant
(4X MSD Reader Buffer with Surfactant diluted 1:2 with distilled water), the
plates were read on the SECTOR Imager 6000 plate reader. Sample concen-
trations were determined using a four-parameter logistic equation and 1/Y2
weighting.
Regeneration Model In Vivo
All procedures involving animals were approved by the Institutional Animal
Care and Use Committee of the Novartis Institutes for Biomedical Research.
See Supplemental Experimental Procedures for additional procedures.
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